Therapeutic Classification: anti-infectives
Pharmacologic Classification: Fluoroquinolones
Absorption: 70% absorbed after oral administration; IV administration results in complete bioavailability.
Distribution: Widely distributed. High tissue and urinary levels are achieved. Crosses the placenta; enters breast milk.
Metabolism/Excretion: —15% metabolized by the liver, 40–50% excreted unchanged by the kidneys.
Half-Life: 4 hr.
Skin/Skin Structure Infections
- PO (Adults ): 500–750 mg every 12 hr for 7–14 days (immediate-release).
- IV (Adults ): 400 mg every 8–12 hr for 7–14 days.
Bone and Joint Infections
- PO (Adults ): 500–750 mg every 12 hr for 4–8 wk (immediate-release).
- IV (Adults ): 400 mg every 8–12 hr for 4–8 wk.
Complicated Intra-Abdominal Infections
- PO (Adults ): 500 mg every 12 hr for 7–14 days (immediate-release).
- IV (Adults ): 400 mg every 12 hr for 7–14 days.
Infectious Diarrhea
- PO (Adults ): 500 mg every 12 hr for 5–7 days (immediate-release).
Typhoid Fever
- PO (Adults ): 500 mg every 12 hr for 10 days (immediate-release).
Uncomplicated Urethral and Cervical Gonorrhea
- PO (Adults ): 250 mg single dose (immediate-release).
Inhalational Anthrax (Post-Exposure)
- PO (Adults ): 500 mg every 12 hr for 60 days (immediate-release).
- PO (Children ): 15 mg/kg (max = 500 mg/dose) every 12 hr for 60 days (immediate-release).
- IV (Adults ): 400 mg every 12 hr for 60 days.
- IV (Children ): 10 mg/kg (max = 400 mg/dose) every 12 hr for 60 days.
Plague
- PO (Adults ): 500–750 mg every 12 hr for 14 days (immediate-release).
- PO (Children ): 15 mg/kg (max = 500 mg/dose) every 8–12 hr for 14 days (immediate-release).
- IV (Adults ): 400 mg every 8–12 hr for 14 days.
- IV (Children ): 10 mg/kg (max = 400 mg/dose) every 8–12 hr for 10–21 days.
Chronic Bacterial Prostatitis
- PO (Adults ): 500 mg every 12 hr for 28 days (immediate-release).
- IV (Adults ): 400 mg every 12 hr for 28 days.
Lower Respiratory Tract Infections
- PO (Adults ): 500–750 mg every 12 hr for 7–14 days (immediate-release).
- IV (Adults ): 400 mg every 8–12 hr for 7–14 days.
Nosocomial Pneumonia
- IV (Adults ): 400 mg every 8 hr for 10–14 days.
Febrile Neutropenia
- IV (Adults ): 400 mg every 8 hr for 7–14 days.
Urinary Tract Infections
- PO (Adults ): Complicated urinary tract infection or acute pyelonephritis—250–500 mg every 12 hr for 7–14 days (immediate-release) or 1000 mg once daily for 7–14 days (extended-release); Acute uncomplicated cystitis—250 mg every 12 hr for 3 days (immediate-release) or 500 mg once daily for 3 days (extended-release).
- PO (Children 1–17 yr): Complicated urinary tract infection or pyelonephritis—10–20 mg/kg (max = 750 mg/dose) every 12 hr for 10–21 days (immediate-release).
- IV (Adults ): 200–400 mg every 8–12 hr for 7–14 days.
- IV (Children 1–17 yr): Complicated urinary tract infection or pyelonephritis—6–10 mg/kg (max = 400 mg/dose) every 8 hr for 10–21 days.
Acute Bacterial Sinusitis
- PO (Adults ): 500 mg every 12 hr for 10 days (immediate-release).
- IV (Adults ): 400 mg every 12 hr for 10 days.
Renal Impairment
- PO (Adults ): CCr 30–50 mL/min—250–500 mg every 12 hr (immediate-release); CCr 5–29 mL/min—250–500 mg every 18 hr (immediate-release) or 500 mg once daily (extended-release); Hemodialysis or peritoneal dialysis—250–500 mg every 24 hr (immediate-release) (give dose after dialysis session)or 500 mg once daily (extended-release) (give dose after dialysis session).
Renal Impairment
- IV (Adults ): CCr 5–29 mL/min—200–400 mg every 18–24 hr.
